IGC Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IGC Pharma, Inc. (IGC) on December 30, 2025. The report addresses a corporate governance decision made by the Board of Directors regarding the Company's fiscal calendar.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly informational regarding a change in fiscal year-end.
Material Changes
- Fiscal Year Change: The Board approved a change in the Company's fiscal year-end from March 31 to December 31.
- Effective Date: The change is effective as of December 31, 2025.
- Transition Period: The Company will file a Transition Report on Form 10-K covering the nine-month period from April 1, 2025, through December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary on future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the announcement of the fiscal year adjustment.
Investor Verification Checklist
- Verify the upcoming Form 10-K Transition Report for the period April 1, 2025, to December 31, 2025.
- Confirm the new fiscal year-end date of December 31 for future reporting cycles.
- Review the Company's historical filings to compare financial performance under the previous March 31 fiscal year-end.